Safety - OPEN Foundation

Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions

Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., ... & McDonald, W. M. | Journal of affective disorders | 19 July 2018

Positive psychology in the investigation of psychedelics and entactogens: A critical review

Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. | Neuropharmacology | 29 June 2018

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. | Neuropharmacology | 5 June 2018

A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens

Barnett, B. S., Siu, W. O., & Pope Jr, H. G. | The Journal of nervous and mental disease | 1 June 2018

The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption

Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018

Peyote’s Race Problem

Dawson, A. | Plant Medicines, Healing and Psychedelic Science: Cultural Perspectives | 29 April 2018

Key interindividual determinants in MDMA pharmacodynamics

Papaseit, E., Torrens, M., Pérez-Mañá, C., Muga, R., & Farré, M. | Expert opinion on drug metabolism & toxicology | 14 February 2018

Evaluating the abuse potential of psychedelic drugs for medical use in humans

Heal, D. J., Gosden, J., & Smith, S. L. | Neuropharmacology | 7 February 2018

Is LSD toxic?

Nichols, D. E., & Grob, C. S. | Forensic science international | 2 February 2018

Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Branchi, I., & Kaelen, M. | Journal of Psychopharmacology | 1 February 2018

Key interindividual determinants in MDMA pharmacodynamics.

Papaseit, E., Torrens, M., Pérez-Mañá, C., Muga, R., & Farré, M. | Expert opinion on drug metabolism & toxicology | 16 January 2017

A regulatory perspective on the evaluation of hallucinogen drugs for human use

Calderon, S. N., Hunt, J., & Klein, M. | Neuropharmacology | 24 November 2017

Regulation of human research with LSD in the United States (1949-1987)

Bonson, K. R. | Psychopharmacology | 17 November 2017

Psychedelic Drugs in Biomedicine

Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. | Trends in Pharmacological Sciences | 22 September 2017

First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects

Boxler, M. I., Liechti, M. E., Schmid, Y., Kraemer, T., & Steuer, A. E. | Journal of proteome research | 1 September 2017

MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘Ecstasy’ users

Roberts, C. A., Quednow, B. B., Montgomery, C., & Parrott, A. C. | Neuroscience & Biobehavioral Reviews | 8 August 2017

Side-effects associated with ketamine use in depression: a systematic review

Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. | The Lancet Psychiatry | 27 July 2017

Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy

Elsey, J. W. | Drug Science, Policy and Law | 26 July 2017

First time view on human metabolome changes after a single intake of 3,4 methylenedioxymethamphetamine (MDMA) in healthy placebo-controlled subjects

Boxler, M. I., Liechti, M. E., Schmid, Y., Kraemer, T., & Steuer, A. E. | Journal of Proteome Research | 19 July 2017